 Shares of Fate Therapeutics Inc. FATE, -1.08 plunged 56.8 in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of its collaboration with Janssen Biotech Inc. and announced job cuts. The company said it had declined Janssens proposal to continue the collaboration on revised terms and conditions. 